89Zr-Labeled Anti-PD-L1 Antibody Fragment for Evaluating In Vivo PD-L1 Levels in Melanoma Mouse Model-Reference-Cited by-同舟云学术

89Zr-Labeled Anti-PD-L1 Antibody Fragment for Evaluating In Vivo PD-L1 Levels in Melanoma Mouse Model

Published:2020-10-01 Issue:8 Volume:35 Page:549-557
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Bridgwater Caleb¹,Geller Anne²,Hu Xiaoling³,Burlison Joe A.³,Zhang Huang-Ge²³,Yan Jun²³⁴,Guo Haixun¹⁵

Affiliation:

1. Department of Radiology, University of Louisville, Louisville, Kentucky, USA.

2. Department of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, USA.

3. James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA.

4. Department of Surgery, University of Louisville, Louisville, Kentucky, USA.

5. Center for Predictive Medicine, University of Louisville, Louisville, Kentucky, USA.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2019.3056

Reference28 articles.

1. PD-1 and PD-L1 antibodies for melanoma

2. Clinical Development of PD-1 in Advanced Melanoma

3. The Programmed Death-1 Immune-Suppressive Pathway: Barrier to Antitumor Immunity

4. The PD-1/PD-L1 Pathway in Human Pathology

5. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of ¹⁷⁷Lu-Labeled Pertuzumab F(ab′)₂ Fragments for HER2-Positive Cancer Targeting: A Comparative In Vitro and In Vivo Study;Cancer Biotherapy and Radiopharmaceuticals;2024-02-01

2. PET Imaging of Peptide Probe Al[¹⁸F]F-NOTA-PCP1 for Monitoring the Engagement of PD-L1 Antibodies in Tumors;Molecular Pharmaceutics;2024-01-30

3. Noninvasive PET imaging of tumor PD-L1 expression with 64Cu-labeled Durvalumab;American Journal of Nuclear Medicine and Molecular Imaging;2024

4. Artificial Intelligence and Radiomics: Clinical Applications for Patients with Advanced Melanoma Treated with Immunotherapy;Diagnostics;2023-09-27

5. An overview of current advances of PD-L1 targeting immuno-imaging in cancers;Journal of Cancer Research and Therapeutics;2023-08